Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Aubuchon Neil William

Mancini Marianna

Lian Brian

ZANTE GREG

Eli Lilly dominates the rapidly growing weight loss drug market with its GLP-1 drugs Mounjaro and Zepbound, generating over $12 billion in quarterly sales. The company recently launched Foundayo, an oral GLP-1 pill, which could cannibalize Zepbound sales but is more likely to expand the patient base by attracting new GLP-1 users. While Lilly faces competition from Novo Nordisk and other pharma companies, analysts view Foundayo as a growth opportunity rather than a threat.

Should Eli Lilly Investors Worry About Its Newest Rival -- From Within?

USC Pharmacy Alumni, Full Time Investor. My tweets are a general reflection of my Investments and not a recommendation. Please do your own due diligence.

Pharmdca

Trading & Investing Education 
Inventor : Ripster Cloud System  
Founder: Tenet Trade Group
https://t.co/0qpaN2fM0W
 https://t.co/GP2vE0fon3

Viking Therapeutics Inc (VKTX) Stock Price, Analysis & Trade Signals